Sr. Director, Patient Marketing Dual Asset Strategy

Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.

We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. 

The Senior Director, Patient Marketing & Commercial Strategy MMN-CIDP Franchise is a senior commercial leader accountable for maximizing growth of Vyvgart Hytrulo in CIDP while strategically preparing for and integrating the launch of Empa in MMN and subsequently CIDP, within a multi-indication therapeutic franchise.

This role sits on the CIDP Indication Strategy Team and JIST, and owns the patient commercial strategy across the portfolio, with primary responsibility for accelerating performance, expanding reach, and strengthening positioning of Vyvgart Hytrulo in CIDP. In parallel, this leader will work with ICTs and cross-functional partners to define the dual-asset strategy and co-positioning framework to ensure the upcoming Empa launch in MMN and CIDP enhances franchise value.

Success in this role requires balancing revenue growth for Vyvgart Hytrulo with long-term CIDP-MMN portfolio strategy, shaping the market to expand category demand, and building a cohesive enterprise narrative that maximizes total franchise growth.

Key Responsibilities

I. Maximize Growth trajectory and peak revenue of Vyvgart in CIDP (Primary)

· Lead the development and evolution of patient commercial strategy to maximize growth across CIDP and MMN.

· Identify and unlock growth levers across awareness, consideration, therapy initiation, persistence, and lifecycle management.

· Strengthen competitive positioning and reinforce differentiated value within the treatment paradigm.

· Drive omnichannel optimization using rigorous performance analytics and agile measurement.

· Expand addressable market through targeted patient segment strategies and ecosystem partnerships.

· Partner closely with HCP, Market Access, Medical, Patient Support Services and Patient Advocacy to remove friction points across the patient journey.

· Co-Lead proactive competitive response planning and scenario modeling.

II. Architect Dual-Asset Co-Positioning Strategy

· Define clear roles, positioning, and treatment sequencing for Vyvgart and Empa across CIDP and MMN.

· Develop a franchise-level value narrative that clarifies differentiation while reinforcing complementary strengths.

· Prevent internal cannibalization through disciplined segmentation and treatment pathway strategy.

· Establish guardrails for patient engagement, messaging, targeting, and lifecycle investment decisions.

· Lead trade-off discussions to optimize enterprise value versus individual brand preference.

III. Shape the Market to Expand Total Franchise Value

· Drive market shaping initiatives that grow category awareness and demand

· Lead disease awareness and unbranded education strategies to increase top-of-funnel volume.

· Identify structural barriers (diagnostic delay, access constraints, patient inertia) and design strategic interventions.

· Influence evidence generation priorities in partnership with Medical and Development to support long-term differentiation.

· Anticipate competitive shifts and adapt ecosystem strategy accordingly.

IV. Launch Integration – Second Asset

· Co-develop Patient Commercial Strategy for Empa MMN launch with disciplined alignment to franchise strategy.

· Ensure Empa launch positioning complements and strengthens the in-market value of Vyvgart Hytrulo.

· Define sequencing, patient targeting, and differentiation strategy.

· Align US strategy with Global framework while advocating for market-specific needs.

V. Enterprise & Strategic Leadership

· Serve as a core strategic voice within the Indication Strategy Team.

· Shape portfolio priorities and resource allocation decisions.

· Provide executive-ready strategic recommendations supported by analytics and scenario modeling.

· Mentor high-performing patient marketing talent.

· Model enterprise mindset, cross-functional influence, and disciplined prioritization.

Core Competencies

· Enterprise Portfolio Optimization: Proven ability to maximize total franchise value.